Colitis por citomegalovirus en trasplante renal: presentación de 2 casos
PDF (Español)
HTML (Español)
PDF

Keywords

Kidney transplantation, cytomegalovirus infections.

How to Cite

1.
García y Otero GA, Aceves Quintero CA, Corona Melendez JC, Amaya Carreño MA. Colitis por citomegalovirus en trasplante renal: presentación de 2 casos. Rev. Colomb. Nefrol. [Internet]. 2020 Jan. 8 [cited 2024 Mar. 28];7(1). Available from: https://revistanefrologia.org/index.php/rcn/article/view/333

Abstract

Cytomegalovirus infection is a latent risk among immunocompromised kidney transplant recipients and is associated with increased risk of allograft failure and death. CMV infection can manifest as active infection or as CMV disease (divided in CMV syndrome and CMV tissue-invasive disease). We present two cases of tissue invasive CMV disease, presenting within 7 months after kidney transplantation. Both cases were D+/R-, received lymphocyte-depleting agents and mycophenolate, and both received CMV prophylaxis according to General Practice Guidelines. CMV disease criteria included detectable viral replication in blood, classical endoscopic findings and histopathological confirmation. We emphasize the need of categorical identification of CMV infection risk factors among kidney transplantation recipients, specially CMV donor/recipient serostatus and immunosuppressive medication. Although clinical practice guidelines suggest 1 to 3 months CMV prophylaxis in high-risk cases, extended prophylaxis and immunosuppressive medication adjustment should be considered.

https://doi.org/10.22265/acnef.7.1.333
PDF (Español)
HTML (Español)
PDF

References

Santos C, Vella J, & Brennan D. Prevention of active infection and disease in kidney transplant recipients. UpToDate 2018. Retrieved from https://www.uptodate.com/contents/prevention-of-active-infection-and-disease-in-kidney-transplant-recipients

Santos C, Vella J, & Brennan D. Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant recipients. UpToDate 2018. Retrieved from https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-management-of-cytomegalovirus-disease-in-kidney-transplant-recipients.

Rao M. Cytomegalovirus infection after renal transplantation - The Indian experience. Indian Journal Of Nephrology 2002;12:16-24.

Le PH, Lin WR, Kuo CJ, Wu RC, Hsu JT, Su MY, et al. Clinical characteristics of cytomegalovirus colitis: a 15-year experience from a tertiary reference center. Therapeutics And Clinical Risk Management 2017;13:1585-1593.

Murray BM, Amsterdam D, Gray V, Myers H, Gerbasi J, Venuto R. Monitoring and renal diagnosis of cytomegalovirus infection in renal transplantation. J Am Soc Nephrol 1997;8(9);1448-1457.

Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001;12(4):848-855.

Bhadauria D, Sharma RK, Kaul A, Prasad N, Gupta A, Gupta A, et al. Cytomegalovirus disease in renal transplant recipients: a single-center experience. Indian J Microbiol 2012;52(3):510-515.

Cofán F, Alonso-Melgar A, Díaz J, Errasti P, Fijo J, Fraile P, et al. Enfermedad por citomegalovirus: efectos directos e indirectos. Nefrología 2012;3(1):4-13.

Hung TW, Chang HR, Wu SW, Lin CK, Lian JD. Cytomegalovirus disease in renal allograft recipients: experience of a single center. Acta Nephrologica 2009;23:21-25.

Merrikhi AR, Amir-Shahkarami SM, Saneian H. Cytomegalovirus colitis in a 10 year-old girl after kidney transplantation. Iran J Pediatr 2012;23(2):220-222.

Chang HR, Lian JD, Chan CH, & Wong LC. Cytomegalovirus ischemic colitis of a diabetic renal transplant recipient. Clinical Transplantation 2004;18(1):100-104.

Jassal SV, Roscoe JM, Zaltzman JS, Mazzulli T, Krajden M, Gadawski M, et al. Clinical Practice Guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998;9:1697-1708.

Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010;77(4):299-311.

Caring for Australians with Renal Impairment (CARI). The CARI guidelines. CMV disease and kidney transplant: prophylaxis for cytomegalovirus infection in patients following renal transplantation. Nephrology (Carlton) 2004;9(Suppl3):S27-S31.

Humar A, Lebranchu Y, Vincenti F, Blumberg E, Punch JD, Limaye AP, et al. The Efficacy and safety of 200 says valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. American Journal Of Transplantation 2010;10(5):1228-1237.

No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.

Dimensions


PlumX


Downloads

Download data is not yet available.